Home
Skip to main content
        

Controlled Substances Board 

The Controlled Substances Board may issue a permit authorizing a person to manufacture, obtain, possess, use, administer or dispense a controlled substance for purposes of scientific research, instructional activities, chemical analysis or other special uses.


Executive Director:      Chad Zadrazil

Board Roster

 

Related Board Information

 




 On August 28, 2014 the DEA published its final rule in the Federal Register placing Suvorexant into Schedule IV of the Federal Controlled Substances Act. The scheduling action was effective September 29, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to treat Suvorexant as a Schedule IV effective November 1, 2014.

 
On August 22, 2014 the DEA published its final rule in the Federal Register rescheduling hydrocodone combination products from Schedule III to Schedule II of the Federal Controlled Substances Act. The scheduling action was effective October 6, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly reschedule hydrocodone combination products from Schedule III to Schedule II effective November 1, 2014.

 
On July 2, 2014, the DEA published its final rule in the Federal Register placing tramadol into schedule IV of the federal Controlled Substances Act effective August 18, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly treat tramadol as a schedule IV controlled substance effective September 1, 2014.

 2013 Wisconsin Act 267, also known as Lydia's Law, charges the Controlled Substances Board with aiding a physician in applying for and processing an investigational drug permit for use of cannabidiol (CBD oil) as treatment for a seizure disorder.
Investigational Drug Permit For Cannabidoil